ArticleJournal of nanobiotechnology2026
Platelet-rich plasma-derived extracellular vesicles delivered niraparib for ultrasound imaging and atherosclerosis treatment.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Macrophage-driven oxidative stress and chronic inflammation play pivotal roles in the progression of atherosclerosis. Given the overactivation of poly (ADP-ribose) polymerase (PARP) in atherosclerosis, PARP inhibitors have potential therapeutic potential, but their efficacy is limited due to poor in vivo targeting. Platelet-rich plasma-derived extracellular vesicles (PEVs), which inherently target inflammatory sites and mitigate oxidative stress, offer a promising delivery platform. Here, we developed NGPPEVs, a nanoplatform that employs PEVs to deliver niraparib, a PARP inhibitor, followed by encapsulation of Ca(HCO₃)₂ to generate gas within cells, thereby combining targeted therapy with ultrasound imaging capabilities. In vitro, NGPPEVs significantly scavenged intracellular reactive oxygen species (ROS) and suppressed pathways related to oxidative stress and cholesterol metabolism. Mechanistically, NGPPEVs suppressed foam cell formation by inhibiting the PARP1-IL-6-CD36 axis, leading to significant downregulation of the key scavenger receptor CD36. In apolipoprotein E-deficient mice fed a high-fat high-cholesterol diet, NGPPEVs demonstrated superior therapeutic efficacy, effectively reducing atherosclerotic plaque area and enhancing plaque stability. Collectively, NGPPEVs have great potential in the precise diagnosis and treatment of atherosclerosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.